NasdaqGS:RGNX

Stock Analysis Report

Executive Summary

REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease.

Snowflake

Fundamentals

Excellent balance sheet with high growth potential.


Similar Companies

Share Price & News

How has REGENXBIO's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

0.03%

RGNX

3.1%

US Biotechs

0.07%

US Market


1 Year Return

-27.6%

RGNX

-1.6%

US Biotechs

8.9%

US Market

Return vs Industry: RGNX underperformed the US Biotechs industry which returned -1.6% over the past year.

Return vs Market: RGNX underperformed the US Market which returned 8.9% over the past year.


Shareholder returns

RGNXIndustryMarket
7 Day0.03%3.1%0.07%
30 Day3.6%0.2%-0.3%
90 Day-20.2%0.9%-1.6%
1 Year-27.6%-27.6%-0.7%-1.6%11.3%8.9%
3 Year136.3%136.3%18.9%14.7%46.3%36.8%
5 Yearn/a-1.8%-6.6%62.1%44.3%

Price Volatility Vs. Market

How volatile is REGENXBIO's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is REGENXBIO undervalued compared to its fair value and its price relative to the market?

23.2%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: RGNX ($38.4) is trading below our estimate of fair value ($49.97)

Significantly Below Fair Value: RGNX is trading below fair value, but not by a significant amount.


Price To Earnings Ratio

PE vs Industry: RGNX is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: RGNX is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate RGNX's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: RGNX is overvalued based on its PB Ratio (2.9x) compared to the US Biotechs industry average (2.6x).


Next Steps

Future Growth

How is REGENXBIO forecast to perform in the next 1 to 3 years based on estimates from 5 analysts?

69.7%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: RGNX is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.7%).

Earnings vs Market: RGNX is forecast to become profitable over the next 3 year, which is considered above average market growth.

High Growth Earnings: RGNX's loss is forecast to worsen by 0% next year.

Revenue vs Market: RGNX's revenue (37.2% per year) is forecast to grow faster than the US market (7.2% per year).

High Growth Revenue: RGNX's revenue (37.2% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: RGNX is forecast to be unprofitable in 3 years.


Next Steps

Past Performance

How has REGENXBIO performed over the past 5 years?

20.6%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Earnings Trend: RGNX is unprofitable, but has reduced losses over the past 5 years at a rate of 20.6% per year.

Accelerating Growth: Unable to compare RGNX's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: RGNX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (83.4%).


Return on Equity

High ROE: RGNX has a negative Return on Equity (-9.82%), as it is currently unprofitable.


Return on Assets

ROA vs Industry: RGNX is currently unprofitable, so its Return on Assets is negative.


Return on Capital Employed

ROCE Improving: RGNX is currently unprofitable, so its Return on Capital Employed is negative.


Next Steps

Financial Health

How is REGENXBIO's financial position?


Financial Position Analysis

Short Term Liabilities: RGNX's short term assets ($359.5M) exceeds its short term liabilities ($24.7M)

Long Term Liabilities: RGNX's short term assets (359.5M) exceeds its long term liabilities (9.9M)


Debt to Equity History and Analysis

Debt Level: RGNX is debt free.

Reducing Debt: RGNX currently has no debt however we can't compare to 5 years ago as we have no data for that period.


Balance Sheet

Inventory Level: RGNX has a low level of unsold assets or inventory.

Debt Coverage by Assets: Insufficient data to determine if RGNX's debt is covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: RGNX has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if RGNX has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Next Steps

Dividend

What is REGENXBIO's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.4%markettop25%3.7%industryaverage2.2%forecastin3Yearsn/a

Current dividend yield vs market & industry


Stability and Growth of Payments

Notable Dividend: Unable to evaluate RGNX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate RGNX's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.

Stable Dividend: Insufficient data to determine if RGNX's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if RGNX's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of RGNX's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

What is the CEO of REGENXBIO's salary, the management and board of directors tenure and is there insider trading?

2.9yrs

Average management tenure


CEO

Ken Mills (44yo)

10.6yrs

Tenure

US$4,938,199

Compensation

Mr. Kenneth T. Mills, also known as Ken, has been the Chief Executive Officer and President at REGENXBIO Inc. since March 2009. Mr. Mills served as the Chief Financial Officer and Vice President of Busines ...


CEO Compensation Analysis

Compensation vs. Market: Ken's total compensation ($USD4.94M) is about average for companies of similar size in the US market ($USD4.07M).

Compensation vs Earnings: Ken's compensation has increased whilst the company is unprofitable.


Management Age and Tenure

2.9yrs

Average Tenure

49.5yo

Average Age

Experienced Management: RGNX's management team is considered experienced (2.9 years average tenure).


Board Age and Tenure

4.5yrs

Average Tenure

65.5yo

Average Age

Experienced Board: RGNX's board of directors are considered experienced (4.5 years average tenure).


Insider Trading

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown


Management Team

  • Curran Simpson (57yo)

    Senior VP of Product Development & Chief Technology Officer

    • Tenure: 4.2yrs
    • Compensation: US$1.90m
  • Ram Palanki

    Senior VP of Commercial Strategy & Operations

    • Tenure: 1.2yrs
  • Patrick Christmas (48yo)

    Senior VP & General Counsel

    • Tenure: 3.2yrs
  • Ken Mills (44yo)

    CEO, President & Director

    • Tenure: 10.6yrs
    • Compensation: US$4.94m
  • Vit Vasista (51yo)

    Chief Financial Officer

    • Tenure: 10.2yrs
    • Compensation: US$1.94m
  • Olivier Danos (61yo)

    Chief Scientific Officer

    • Tenure: 2.6yrs
    • Compensation: US$1.61m
  • Stephen Yoo (41yo)

    Consultant

    • Tenure: 0.8yrs
    • Compensation: US$1.88m
  • Laura Coruzzi

    Senior Vice President of Intellectual Property

    • Tenure: 3.4yrs
  • Andrew Yost

    Vice President of Corporate Development

    • Tenure: 2.6yrs
  • Shiva Fritsch

    Senior Vice President of Human Resources

    • Tenure: 2yrs

Board Members

  • Don Hayden (63yo)

    Independent Chairman of the Board

    • Tenure: 6.7yrs
    • Compensation: US$470.58k
  • Dave Stump (69yo)

    Independent Director

    • Tenure: 4yrs
    • Compensation: US$442.08k
  • Dan Abdun-Nabi (64yo)

    Independent Director

    • Tenure: 3.2yrs
    • Compensation: US$438.08k
  • Jerry Karabelas (67yo)

    Independent Director

    • Tenure: 4.4yrs
    • Compensation: US$438.58k
  • Inder Verma (71yo)

    Member of Scientific Advisor

    • Tenure: 0yrs
  • Luke Beshar (60yo)

    Independent Director

    • Tenure: 4.5yrs
    • Compensation: US$450.58k
  • Allan Fox (71yo)

    Director

    • Tenure: 10.7yrs
    • Compensation: US$430.58k
  • Judith Swain (70yo)

    Member of Scientific Advisor

    • Tenure: 0yrs
  • Daniel Tassé (59yo)

    Independent Director

    • Tenure: 3.2yrs
    • Compensation: US$435.58k
  • Ken Mills (44yo)

    CEO, President & Director

    • Tenure: 10.6yrs
    • Compensation: US$4.94m

Company Information

REGENXBIO Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: REGENXBIO Inc.
  • Ticker: RGNX
  • Exchange: NasdaqGS
  • Founded: 2008
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$1.413b
  • Shares outstanding: 36.81m
  • Website: https://www.regenxbio.com

Number of Employees


Location

  • REGENXBIO Inc.
  • 9600 Blackwell Road
  • Suite 210
  • Rockville
  • Maryland
  • 20850
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
RGNXNasdaqGS (Nasdaq Global Select)YesCommon SharesUSUSDSep 2015
RB0DB (Deutsche Boerse AG)YesCommon SharesDEEURSep 2015

Biography

REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic p ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/10/23 00:38
End of Day Share Price2019/10/22 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.